Systemic psoriasis biomarkers differentially impact clinical responses to deucravacitinib and apremilast in moderate-to-severe plaque psoriasis: Insight from phase 3 studies
- DOI
- 10.1016/j.jid.2026.10.035
- Published
- 2026-11
- Container
- Journal of Investigative Dermatology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.jid.2026.10.035,
title = {Systemic psoriasis biomarkers differentially impact clinical responses to deucravacitinib and apremilast in moderate-to-severe plaque psoriasis: Insight from phase 3 studies},
author = {Yi Luo and Aditi B. Bal and Peter Schafer and James G. Krueger},
year = {2026},
journal = {Journal of Investigative Dermatology},
doi = {10.1016/j.jid.2026.10.035},
url = {https://doi.org/10.1016/j.jid.2026.10.035}
}RIS
TY - JOUR TI - Systemic psoriasis biomarkers differentially impact clinical responses to deucravacitinib and apremilast in moderate-to-severe plaque psoriasis: Insight from phase 3 studies AU - Yi Luo AU - Aditi B. Bal AU - Peter Schafer AU - James G. Krueger PY - 2026 JO - Journal of Investigative Dermatology DO - 10.1016/j.jid.2026.10.035 UR - https://doi.org/10.1016/j.jid.2026.10.035 ER -
APA
Luo, Y., Bal, A. B., Schafer, P., & Krueger, J. G. (2026). Systemic psoriasis biomarkers differentially impact clinical responses to deucravacitinib and apremilast in moderate-to-severe plaque psoriasis: Insight from phase 3 studies. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2026.10.035
Source records
- crossref · retrieved 2026-11-10T14:06:46.127Z